Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1997-07-02
1999-01-12
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
514170, 514841, 514843, A61K 920, A61K 3156
Patent
active
058584056
ABSTRACT:
This invention provides a bridged triphasic combination progestin/estrogen oral contraceptive regimen comprising the administration of a contraceptive progestin/estrogen combination for 23-25 days consecutive days beginning on the first day of menses, followed by the administration of an estrogen for 3-5 days following the administration of the estrogen/progestin combination, so that the total period of administration is 28 days per 28 day cycle. Particularly preferred progestins of this invention are trimegestone, dienogest, and drospirenone.
REFERENCES:
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4248790 (1981-02-01), Ponsold et al.
patent: 4273771 (1981-06-01), Coussediere
patent: 4390531 (1983-06-01), Edgren
patent: 4530839 (1985-07-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4921843 (1990-05-01), Pasquale
patent: 4962098 (1990-10-01), Boissonneault
patent: 5262408 (1993-11-01), Bergink
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5418228 (1995-05-01), Bennink
patent: 5583129 (1996-12-01), Spona et al.
patent: 5747480 (1998-05-01), Gast
Sartoretto et al., Clinical evaluation of a low dosage estrogen-progesterone association (100.mu.g of d-norgestrel and 20.mu.g
American Home Products Corporation
Milowsky Arnold S.
Page Thurman K.
Spear James M.
LandOfFree
Oral contraceptive does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral contraceptive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral contraceptive will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512332